Company intelligence / Profile preview

Biois

Ownership: Public · BIOS
Development stage: Other

Overview

BIOS is a Hong Kong-based biotech specializing in hemoglobin-based oxygen carrier therapeutics and devices. Its animal product Oxapex® is approved in New Zealand and has minor use permits from APVMA and US FDA. Oxamex® was approved by the EMA's CVMP and UK VMD for treating hemorrhagic shock in dogs. The lead human candidate YQ23® completed Phase I trials in the UK and is undergoing Phase Ib/IIa trials for advanced solid tumors and critical limb ischemia. Other programs are at preclinical stages.

Therapeutic areas: PulmonologyHematologyOncologyCardiovascular
Modalities: Protein (hemoglobin-based oxygen carriers)BiologicMedical device (extracorporeal circulation products)
Industry: Biotech

Financials

Market cap: $209.1M
Total revenue: $0
Enterprise value: $214.3M

Beyond the preview

Go deeper on Biois.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biois.

Explore the full profile